262 related articles for article (PubMed ID: 18772354)
1. New (alternative) temozolomide regimens for the treatment of glioma.
Wick W; Platten M; Weller M
Neuro Oncol; 2009 Feb; 11(1):69-79. PubMed ID: 18772354
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide dosing regimens for glioma patients.
Strik HM; Marosi C; Kaina B; Neyns B
Curr Neurol Neurosci Rep; 2012 Jun; 12(3):286-93. PubMed ID: 22437507
[TBL] [Abstract][Full Text] [Related]
3. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
Hegi ME; Liu L; Herman JG; Stupp R; Wick W; Weller M; Mehta MP; Gilbert MR
J Clin Oncol; 2008 Sep; 26(25):4189-99. PubMed ID: 18757334
[TBL] [Abstract][Full Text] [Related]
4. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
[TBL] [Abstract][Full Text] [Related]
5. O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas.
Fan CH; Liu WL; Cao H; Wen C; Chen L; Jiang G
Cell Death Dis; 2013 Oct; 4(10):e876. PubMed ID: 24157870
[TBL] [Abstract][Full Text] [Related]
6. Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.
Robinson CG; Palomo JM; Rahmathulla G; McGraw M; Donze J; Liu L; Vogelbaum MA
Br J Cancer; 2010 Aug; 103(4):498-504. PubMed ID: 20628383
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
9. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
[TBL] [Abstract][Full Text] [Related]
10. Rechallenge with temozolomide in recurrent glioma.
Gaviani P; Silvani A; Lamperti E; Botturi A; Fariselli L; Simonetti G; Ferrari D; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S247-9. PubMed ID: 21987286
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
[TBL] [Abstract][Full Text] [Related]
12. Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Wang HW; Xu ZK; Song Y; Liu YG
Cancer Gene Ther; 2017 May; 24(5):215-220. PubMed ID: 28409559
[TBL] [Abstract][Full Text] [Related]
13. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
Zapanta Rinonos S; Li T; Pianka ST; Prins TJ; Eldred BSC; Kevan BM; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
J Neurooncol; 2024 Jan; 166(1):129-142. PubMed ID: 38224404
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Fiano V; Trevisan M; Trevisan E; Senetta R; Castiglione A; Sacerdote C; Gillio-Tos A; De Marco L; Grasso C; Magistrello M; Tondat F; Rudà R; Cassoni P; Soffietti R; Merletti F
J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517
[TBL] [Abstract][Full Text] [Related]
15. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
[TBL] [Abstract][Full Text] [Related]
16. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
Jiang G; Li LT; Xin Y; Zhang L; Liu YQ; Zheng JN
Curr Med Chem; 2012; 19(23):3886-92. PubMed ID: 22788764
[TBL] [Abstract][Full Text] [Related]
17. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Fukushima T; Takeshima H; Kataoka H
Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
[TBL] [Abstract][Full Text] [Related]
18. [MGMT analysis in gliomas].
Quillien V; Vauléon E; Saikali S; Lesimple T; Hamlat A; Etcheverry A; Mosser J
Bull Cancer; 2011 Mar; 98(3):291-303. PubMed ID: 21459716
[TBL] [Abstract][Full Text] [Related]
19. Recurrent PNET with MGMT methylation responds to temozolomide.
Oh J; Bilbao JM; Tsao MN; Fazl M; Guiot MC; Del Maestro RF; Perry JR
Can J Neurol Sci; 2009 Sep; 36(5):654-7. PubMed ID: 19831139
[No Abstract] [Full Text] [Related]
20. Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease.
Kubota Y; Aoki Y; Masaki N; Obara K; Hamada K; Han Q; Bouvet M; Tsunoda T; Hoffman RM
Biochem Biophys Res Commun; 2024 Feb; 695():149418. PubMed ID: 38176171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
